Drug Delivery Partnering Agreements in Pharma and Biotech

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Overview of drug delivery dealmaking

• 2.1. Introduction
• 2.2. The anatomy of drug delivery partnering
• 2.3. Drug delivery or specialty pharma?
  • 2.3.1. Is specialty pharma the only way for drug delivery?
  • 2.3.2. Best practice for optimizing drug delivery program development
  • 2.2.3. The anatomy of a drug delivery deal
    • 2.2.3.a. Case study 1: Alpharma - Durect - September 2008
    • 2.2.3.b. Case study 2: Bayer - MDRNA - August 2007
    • 2.2.3.c. Case study 3: Aradigm - Lung Rx - August 2007

Chapter 3 - Trends in drug delivery dealmaking

• 3.1. Introduction
• 3.2. Drug delivery partnering since 2000
• 3.3. Most active drug delivery dealmakers
• 3.4. Bigpharma drug delivery dealmaking activity
• 3.5. Bigpharma not active in drug delivery
• 3.6. Drug delivery partnering by deal type
  • 3.6.1. Option and evaluation drug delivery partnering
• 3.7. Drug delivery partnering by disease type
• 3.8. Drug delivery M&A activity since 2000

Chapter 4 - Leading drug delivery deals

• 4.1. Introduction
• 4.2. Top drug delivery deals by value
• 4.3. Top drug delivery involving bigpharma
• 4.4. Leading drug delivery M&A deals by value

Chapter 5 - Bigpharma drug delivery deals

• 5.1. Introduction
• 5.2. How to use bigpharma drug delivery partnering deals
• 5.3. Bigpharma partnering company profiles
  • Abbott
  • Actavis
  • Alcon Labs
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono
  • Mitsubishi Tanabe
  • Mylan
  • Novartis
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Ratiopharm
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Servier
  • Shire
  • Solvay
  • Takeda
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 6 - Drug delivery company deals

• 6.1. Introduction
• 6.2. How to use drug delivery company partnering deals
• 6.3. Drug delivery partnering company profiles
  • 3M Drug Delivery Systems
  • Alkermes
  • Altea Pharmaceuticals
  • Alza
  • Aradigm
  • Bioject
  • Biovail
  • Cardinal Health
  • Cima Labs
  • Connetics
  • Cydex Pharmaceuticals
  • Depomed
  • Dor Biopharma
  • Durect
  • Emisphere
  • Enzon
  • Ethypharm
  • Eurand
  • Generex
  • Inovio (formerly Genetronics)
  • Ivax
  • Macrochem
  • Macromed
  • MDRNA (formerly Nastech)
  • Nektar
  • Nexmed
  • Noven
  • Penwest
  • Pherin Pharmaceuticals
  • Psivida
  • QLT
  • Skyepharma
  • Watson Pharmaceuticals
  • Zogenix

Chapter 7 - Drug delivery dealmaking directory

• 7.1. Introduction
• 7.2. Company A-Z
• 7.3. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
• 7.4. By deal type
  • Asset and product purchase
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Option
  • Research
  • Supply
• 7.5. By therapy area
  • Cardiovascular
  • Central nervous system
  • Dermatology
  • Gastrointestinal
  • Genitourinary
  • Hematology
  • Immunology
  • Infection
  • Inflammation
  • Metabolic
  • Musculoskeletal
  • Oncology
  • Ophthalmics
  • Respiratory
  • Animal health

Chapter 8 - Drug delivery partnering resource center

• 8.1. Online drug delivery partnering
• 8.2. Drug delivery partnering events
• 8.3. Further reading on drug delivery dealmaking

Appendices

• Appendix 1 - Deal type definitions
• Appendix 2 - Example drug delivery partnering agreement
• About CurrentPartnering
• Recent titles from CurrentPartnering

Figures in report

• Figure 1: Components of the typical drug delivery deal structure
• Figure 2: Best practice for drug delivery program development
• Figure 3: Drug delivery partnering since 2000
• Figure 4: Most active drug delivery dealmakers 2003-2008
• Figure 5: Most active bigpharma signing drug delivery deals 2003-2008
• Figure 6: Bigpharma - top 50 - drug delivery deals 2003 to 2008
• Figure 7: Inactive bigpharma in drug delivery dealmaking 2003-2008
• Figure 8: Drug delivery partnering by deal type since 2003
• Figure 9: Drug delivery option deals since 2003
• Figure 10: Drug delivery partnering by disease type from 2003
• Figure 11: Drug delivery M&A since 2000
• Figure 12: Top drug delivery deals by value since 2000
• Figure 13: Top drug delivery deals signed by bigpharma value since 2000
• Figure 14: Top drug delivery M&A deals by value since 2000
• Figure 15: Online partnering resources
• Figure 16: Forthcoming partnering events
• Figure 17: Deal type definitions
• Figure 18: Drug delivery partnering agreement between Solvay and Depomed, November 2008